WO2010057447A1 - Vacunas unitemporales - Google Patents
Vacunas unitemporales Download PDFInfo
- Publication number
- WO2010057447A1 WO2010057447A1 PCT/CU2009/000008 CU2009000008W WO2010057447A1 WO 2010057447 A1 WO2010057447 A1 WO 2010057447A1 CU 2009000008 W CU2009000008 W CU 2009000008W WO 2010057447 A1 WO2010057447 A1 WO 2010057447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mucosal
- dose
- afcoi
- ova
- afpll
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Definitions
- This invention relates to the field of new vaccines, specifically with the obtention and use of unitemporal vaccines for the treatment or prevention of infections of different nature, as well as for the treatment of tumors. More particularly, this is related to a unitemporal vaccine strategy that solves the problems of inefficient multidose vaccinations, when the absence or loss of the subjects occurs at successive doses and makes current parenteral vaccines more efficient by also inducing mucosal responses using combinations of efficient mucosal adjuvants and parenteral formulations with vaccine antigens included, conjugated or co-administered.
- the nasopharyngeal route is not an alternative for the vaccination of intestinal germs, which is mainly the oral one (Brandtzaeg P et al. Immunol Today, 1999,20: 141-151). Therefore, understanding the mechanisms of mucosal immunity and the development of mucosal vaccines represents one of the biggest challenges in vaccinology.
- the presence of innate mechanisms and systemic specific IgG are also involved in mucosal protection. So the parenteral route, without generally inducing IgAS protects against infectious diseases; but it does not eliminate bearer stages.
- the carriers, when carrying the germ without generally suffering from the disease are those with the greatest epidemiological risk because they are constant disseminators of the infection.
- Adjuvants are involved in: stimulating the innate response (Immunopotentiators); properly distribute the antigens (Delivery System) (Pashine A Valianti NM. Nat. Med. 2005,1 l: S63-68; Singh M and O'Hagan DT. Pharm. Res. 2002,19 (6 ): 715-728) and direct the immune response towards the desired protective responses (Immunopolarization) (O Pérez, et al. PharmacologyOnline, 2006.3: 762-64).
- the development of immunopotentiators or delivery systems that are effective by mucosal route is another main objective of the development of vaccines and of global pharmaceutical companies.
- the alternative routes of immunization are based on the fact that parenteral immunization by requiring syringes and needles induces: fear in the recipient population, especially in prophylactic vaccines and the possibility of reusing needles in certain regions or groups, with the consequent increase of the risk of disease transmission.
- Alternative routes include: oral, nasal, vaginal, rectal, transdermal and sublingual, among others.
- the regionalization of the mucosal response has led to finding evidence that infections that occur through the airways are better protected by nasal immunizations, which also induce protection in the female genital tract (Brandtzaeg P, Pabst R. TRENDS in Immunology. 2004.25 (11): 570-577).
- the mucosal immune response is generally the induction of Tolerance. It is carried out with responses of IgAS at the level of the mucous membranes and non-induction of systemic IgG that makes it effective against the multiple commensal germs that the organism has, in particular the human one.
- induction of systemic specific IgG, in addition to IgAS, is an important pillar in mucosal immunization.
- IgA contains a J chain and a secretory component involved in transport to the mucosal lumen, where it is known as IgAS.
- IgA can be presented in monomeric or multimeric form and has two subclasses: IgAi and IgA 2 . The latter is more resistant to proteases produced by various microorganisms.
- IgAS is almost exclusively induced by infections or mucosal immunizations and there is consensus that this antibody is the main protector of mucous membranes.
- the IgA detected in saliva represents the best marker to measure the induction of immune response in the nasopharynx and it is desired to find a good marker for oral immunization (Brandtzaeg P. Int. J. Med. Microbiol. 2003,293: 3-15) .
- Adjuvants are substances that enhance the specific immune response against an antigen causing a faster induction of the antigen and increasing its duration (Vogel FR. Dev. Biol. Stand. 1998,92: 241-248). Alumina continues to be the most commonly used adjuvant in parenteral vaccines. However, this is not a potent adjuvant that could help new vaccines by subunits. It is considered that it only has distribution system properties, although a new mechanism of action independent of ToI-like receptors that involves Nalp3 (Eisenbarth SC et al. Nature, 2008,453: 1122-1126) has recently been described. Its mucosal utility has also not been proven and it is assumed that it preferentially induces a Th2 response. Licensed vaccine adjuvants are scarce (MF59, ASO2, virosome, AFPLl, AFCoI,
- ThI a preferential ThI response in murine and human by parenteral administration characterized by: IgG and ThI subclasses anti PL, production of interferon gamma (IFN ⁇ ), cytokine (IL) 12, tumor necrosis factor alpha (TNF ⁇ ), positive test of delayed hypersensitivity and additionally, the induction of cytotoxic T lymphocytes (CTL)
- IFN ⁇ interferon gamma
- IL cytokine
- TNF ⁇ tumor necrosis factor alpha
- CTL cytotoxic T lymphocytes
- the vaccine, VA-MENGOC-BC ® based on the PL of N. meningitidis serogroup B has been applied in more than 60 million doses and has proven to be safe, non-reagenic and effective to protect against N. meningitidis serogroups B and C. It is also applied during breastfeeding safely and effectively, where it converts the T-independence of Polysaccharide C into a T-dependent antigen (Pérez O. et al. ThI response induced by the B component of VA-MENGOC-BC ® overcomes the thymus independence of polysaccharide C and primes for memory in toddler Applied Biotechnology 2002; 19 (l-2): 54).
- This vaccine induces a pattern preferential ThI characterized by induction in human and animal lymphoproliferation; anti-PL IgG antibodies; IgG subclasses in humans and IgG2a in mice; IFN ⁇ , IL2 and IL12 in the field of messenger ribonucleic acid (mRNA) and proteins, non-induction of anti-PL IgE or increases in total IgE and non-production of IL-4 or IL-5 both at the level of ribonucleic acid messenger (mRNA) as a protein (Pérez O et al. Infec ⁇ Immun. 2001, 69 (72001): 4502-4508).
- mRNA messenger ribonucleic acid
- Proteoliposomes and derivatives thereof, such as cochleates, have also been used as adjuvants as disclosed in the certificate of the author of the invention OCPI 23313, 2008 Pérez Mart ⁇ n OG y cois, and WO / 2004/047805.
- Chitosan is the most abundant biopolymer in nature after cellulose and is part of the exoskeleton of crustaceans and insects and the cell wall of some microorganisms such as yeasts and fungi.
- alkaline deacetylation of chitin N-acetyl-D-glucosamine polymers of different molecular weights and different degrees of deacetylation are obtained, which gives it particular properties. Because it lacks toxicity and allergenicity, it has numerous applications in the pharmaceutical, medical and veterinary industries.
- Chitosan is widely used in research as a transport system for drugs, peptides, proteins, vaccines and DNA, due to its natural mucoadhesive properties.
- As a mucous adhesive multimeter it is used to increase the absorption of morphine and insulin through the epithelium of the nasal mucosa. Increases transepithelial transport of antigens to mucosal immune tissues through tight junctions and by decreased mucosyl movement. It induces immune system stimulating effects such as macrophage activation and cytokine induction.
- the technical objective pursued is to increase vaccine coverage and induce combined mucosal and parenteral responses against heterologous (fungal, antigens). viral, protozoan, helminthic or carcinogenic) or own, especially inducing secretory IgA response (IgAS) involved in protections of mucous germs and cancers originally mucosal or that secondarily invade mucous membranes, also ensuring systemic response of specific IgG antibodies, also involved in mucosal protections.
- IgA response secretory IgA response
- Proteoliposomes and its derivatives (Cochleate [AFCoI] as adjuvants in formulations with heterologous (fungal, viral, bacterial, protozoal, helminthic or carcinogenic) antigens, inserted in their structure, conjugated or co-administered with these or the own antigens existing in the PL and its derivatives
- These formulations extend the preferential response T type 1 (ThI) helper induced by the PL to the own or included antigens (Pérez O et al. Infec ⁇ Immun. 2001, 69 ( 7): 4502-4508), the preferential mucosal of the Cochleate (Pérez O et al.
- the present invention has as its object the use of natural or genetically modified bacterial PLs (AFPLl), in particular those derived from N. meningitidis, or other gram-negative bacteria, as well as Cochleates derived therefrom, as new adjuvants or vaccinated / " I know to get unitemporal vaccines.
- AFPLl natural or genetically modified bacterial PLs
- Proteoliposome, PL it is understood that these are obtained from bacteria using any method known as: isolation without detergent; a process that includes detergent (such as deoxycholate, SDS, etc.) or the extraction from vesicles ("bleb") of crop supernatants and particularly those disclosed in US 5,597,572.
- PLs contain different Pathogen-Associated Molecular Patterns (PAMP), molecular structures conserved between pathogens capable of strongly stimulating the innate immune system and thereby inducing a powerful adaptive response.
- PAMP Pathogen-Associated Molecular Patterns
- PLs contain structures of the outer membrane of bacteria, but for the purposes of this patent, those extracted from other organisms such as viruses, fungi, protozoa, helminths or tumor cells are also considered.
- AFPL is reserved for the use of PL as an adjuvant.
- Cochleate is meant a derivative of a PL that therefore also contains several PAMPs as referred to in the patent (WO / 2004/047805), Pérez O et al. I infected Immun. 2001, 69 (7): 4502-4508 and Pérez O et al. Immunology and cell Biology. 2004, 82: 603-610). Also, for the purposes of this patent, the concept of Cochleate extends to their production from combinations of synthetic lipids with the inclusion of PAMP that act synergistically, which radically differentiates them from other Cochleates produced from lipids. synthetic and not included in the patent referred to above.
- This concept extends to other vaccines that use adjuvants other than those referred to (Proteoliposomes (AFPLs ⁇ and their derivatives (AFCos).) This concept excludes single-dose vaccines that are obviously also applied in a single time.
- the mucous and parenteral system are organized differently and even the mucosal is more compartmentalized.
- the induced responses in the upper respiratory tract are considered to be the best to protect against respiratory infections and that digestive ones require oral immunization. Therefore, it was unexpected to find that the simultaneous application by both routes, mucosal and parenteral are potentiated and even more, that responses enhanced by the application of formulations by several mucosal routes (nasal, oral, sublingual) next to the parenteral are achieved.
- Parenteral and mucosal responses induced by immunization are independent. Both routes generally require several doses and induce cellular responses that result in generally different antibody responses.
- the parenteral pathway induces systemic specific IgG responses and the mucosal pathway, particularly the nasal one, induces specific regional and distant IgAS responses (genitourinary tract) and also systemic specific IgG. Therefore, it was not surprising to find systemic specific IgG responses, as these could be the sum of the responses induced by both immunization routes; but it was surprising and unexpected that a single nasal dose was enhanced at the level of at least two nasal doses by parenteral application.
- Unimmunogenic antigens such as Ovalbumine (Ova) or immunogenic such as tetanus toxoid were efficiently evaluated in this unitemporal strategy. These work incorporated or conjugated with the PL and then transformed into Cochleates or co-administered with them.
- Ovalbumine Ova
- immunogenic such as tetanus toxoid
- Vaccine formulations of the present invention can be used to protect a mammal susceptible to infection or treat tumor diseases by administering said formulation unitemporally.
- These applications may include injections by intramuscular, intraperitoneal, intradermal, subcutaneous or transcutaneous routes with oral, nasal, rectal, vaginal or sublingual mucosal administration, among others.
- the number of doses is usually two or several by similar or different mucosal routes and one parenteral with single or combined antigens.
- the mucosal and systemic immune response induced by similar simultaneous (unitemporal) applications or only one of the ways to amplify the initially induced memory response may be reinforced.
- the novelty of the invention lies primarily in the simultaneous, unitemporal use of an immunization applied by two or more immunization routes.
- an mucosal antigen oral, sublingual, vaginal, reacta ⁇ or nasal
- parenteral subcutaneous, transdermal, intraperitoneal, intradermal or intramuscular
- Another aspect of novelty is that the unitemporal application of an antigen mucosally and simultaneously parenterally, also induces a regional and distant mucosal immune response that is only achieved with at least 2 and better with 3 mucosal doses. For this potentiation there is no current explanation at the level of lymphocyte circulation guided by cytokine and chemokine signals.
- Another novel aspect is that the unitemporal immunization strategy allows the use of several antigens by a single or several mucosal routes and the application of the corresponding antigens parenterally in a combined vaccine.
- Mucosal administration (one or several) is combined with parenteral administration at the same time of vaccination, obtaining enhanced specific responses of mucosal IgAS and systemic IgG.
- Two adjuvants with similar compositions or the same are used, instead of two different adjuvant systems or vectors applied in traditional sensitization-amplification assays.
- AFPLl The effectiveness of the AFPLl, one of the proposed adjuvants is safe in children under one year of age, from 2 to 4 years old, in school children, adolescents and adults and the other one derived from it (AFCoI) has already passed the stability and toxicity tests preclinical and is intended to be used mucosally which is less reactive and does not even require sterility, but to ensure a controlled microbial load.
- Example 1 Obtaining Proteoliposomes (PL). To obtain the PL a culture of N. meningitidis of any serogroup is carried out, particularly the B, Salmonella Typhi, Vibrio cholerae, Echerichia coli, Shiguella, Salmonella or Bordetella pertusus and the biomass collected by centrifugation is subjected to an extraction process with detergent, enzymes and ultrasound.
- PL Proteoliposomes
- the Proteoliposome thus obtained contains: porins (PorA and PorB); traces of bacterial DNA and less than 10% (in relation to proteins) of native LPS inserted in its structure; But never free.
- the porins, the DNA and the LPS present are PAMP that interact with the pattern recognition receptors triggering the warning signals at the level of the cells involved in the innate response.
- the final product is subjected to a set of biological and physical-chemical controls.
- the antigen of interest can be increased up to at least 35% relative to the proteins.
- a similar procedure to obtain liposomal structures enriched in outer membrane proteins has been used based on viruses and protozoa.
- Example 2 Obtaining Cochleate derived from Proteoliposome. Starting from PL obtained by the methods described in EP 885900077.8 or US 5,597,572. These are resuspended in Tris-EDTA buffer solution with 0.5% sodium deoxycholate. The protein concentration of the suspension was determined using the Lowry methodology modified according to
- the dialysis was performed by rotational agitation or tangential filtration for 24 h with continuous and slow change of the dialysis buffer in the first or several washes in the second.
- This last solution consisted of 50-150 mM NaCl, 1-4 mM Imidazole, 3-5 mM HEPES and 2-7 mM CaCl in H 2 O prepared under sterility conditions that were preserved during all steps. Cochleate formation was verified by the formation of a white precipitate and subsequent microscopic observation, both optical and electronic. The protein and phospholipid concentration was again estimated and adjusted for subsequent tests.
- the physicochemical properties of the proteins included in the Cochleate were checked and compared with those of the PL by electrophoresis in polyacrylamide gels stained with Coomassie Blue. Additionally, the structural integrity of these was checked and verified through the Western Blot methodology.
- Example 3 The application of AFPLl, AFCoI or VA-MENGOC-BC ® intramuscularly induces specific response of serum IgG in mice.
- AFPLl 50 ⁇ L of AFPLl, AFCoI or VA-MENGOC-BC ® (Va) by deep intramuscular puncture in one of the animal's hind limbs, with an interval of 14 days.
- Blood extraction and processing method to obtain the serum Blood collection was performed 21 days after the last dose by puncturing the retroorbital plexus using heparinized capillaries. Blood samples obtained were incubated for 1 h at 37 0 C, then centrifuged at 2000 g for 10 min to extract serum. Detection of anti PL IgG by ELISA: Reagents and Solutions:
- Coating buffer solution 11 mM Na 2 CO 3 , 35 mM NaHCO 3 (pH 9.6) Phosphate Buffered Saline (SSTF) 0.15 M (pH 7.2) Blocking solution (SSTF / 1% SAB): SSTF 0.15 M (pH 7.2), 1% Bovine Seroalbumine (w / v)
- wash solution (SSTF, 0.1% Tween 20): SSTF, 0.1% Tween 20 (v / v), pH 7.4)
- Sample dilution solution (SSTF, 1% SAB, 0 to 20 Tween , 1%) Anti-mouse IgG conjugated to peroxidase (Sigam, St. Louis, MO, USA)
- Substrate buffer solution, STS Na 2 HPO 4 52 mM and citric acid 25 mM (pH 5.6)
- Stop solution H 2 SO 4 2 M.
- Standard antibody serum A curve made with double serial dilutions of a hyperimmune mouse serum, obtained from a reference serum for meningo serogroup B, from the Atlanta Center for Disease Control, in English "Center for Disease Control (CDC) "Methodology:
- the Standard Antibody Serum and the sera to be evaluated are diluted 1: 100 in sample dilution solution. 100 ⁇ L / well are applied in duplicate of the dilutions of the individual sera and the reference serum and incubate 2 h at 37 ° C
- the reaction is stopped by adding 50 ⁇ L of a stop solution.
- the optical density absorbance (OD) measurement is performed at 492 nm in a microplate reader (Titertek, Multiskan Plus)
- the parallel behavior between the curves was evaluated and the linear fit equation was calculated, as well as the coefficient R 2 .
- the standard CDC 1992 serum was defined as the independent variable (x) and the standard Finlay serum as the dependent variable (y).
- the final concentration was determined by substituting in the formula obtained by the values of the 1992 CDC standard for specific IgG.
- 5000 U / mL of anti-PL IgG antibodies were assigned to the maximum point of the curve and 31.25
- AChleate applied intramuscularly induced similar specific IgG responses as the vaccine, VA-MENGOC-BC ® and these were significantly superior to those induced by Proteoliposome (AFPLl).
- Example 4 The application of AFPLl, AFCoI or VA-MENGOC-BC ® intramuscularly does not induce specific secretory IgA response in mouse saliva.
- mice were immunized with two doses of 12.5 ⁇ g / 50 ⁇ L of AFPLl, AFCoI or VA-MENGOC-BC ® (Va) by deep intramuscular puncture in one of the animal's hind limbs, with an interval of 14 days
- Coating buffer solution 11 mM Na 2 CO 3 , 35 mM NaHCO 3 (pH 9.6) Phosphate Buffered Saline (SSTF) 0.15 M (pH 7.2)
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- Washing solution (SSTF, 0.1% Tween 20): SSTF, 0.1% Tween 20 (v / v), pH 7.4) Sample dilution solution (SSTF, 1% SAB, 0.1% Tween 20)
- Anti-IgA R5-140 of biotinylated peroxidase-conjugated mouse (Sigma, St. Louis, MO, USA) Streptavidin-peroxidase (Sigama, St. Louis, MO, USA)
- Standard Antibody Saliva As an internal antibody standard, for the IgA anti PL assays, a curve made with saliva samples from hyperimmune mice was used. Methodology:
- Standard Antibody Saliva and saliva to be evaluated were diluted 1: 2 in. Sample dilution solution. 100 ⁇ L / well is applied in duplicate of the dilutions of the individual sera and the reference serum and incubated 2 h at 37 ° C.
- Example 5 Cochleate (AFCoI) intranasally induces specific IgA response in saliva superior to Proteoliposome (AFPL1) in mice.
- mice were immunized with AFPLl or AFCoI intranasally (IN).
- IN route three doses were administered with a 7-day interval between them, each dose with a concentration of 50 ⁇ g of total proteins for both formulations in a total volume of 25 ⁇ L per mouse, and applied directly to the nostrils with an automatic pipette and sterile tips (12.5 ⁇ L per pit).
- Method of Extraction and processing of saliva Proceed as described in example 4.
- Immunization Protocol Balb / c mice were immunized with AFPLl or AFCoI intranasally (IN).
- IN route three doses were administered with a 7-day spacing between them, each dose with a concentration of 50 ⁇ g of total proteins in both formulations in a total volume of 25 ⁇ L per mouse, and applied directly to the nostrils with an automatic pipette and sterile tips (12.5 ⁇ L per pit)
- Example 7 The intramuscular route requires two doses of Proteoliposome (AFPLl) or Cochleate (AFCoI) to induce a good serum specific IgG response in mice.
- AFPLl Proteoliposome
- AFCoI Cochleate
- mice were immunized with AFPLl or AFCoI intramuscularly (IM) by deep puncture in one of the animal's hind limbs. Each formulation was administered using two immunization schedules of one and two doses respectively per group, the latter with an interval of 14 days. The dose used had a concentration of 12.5 ⁇ g / 50 ⁇ L for each formulation.
- Method of Extraction and processing of blood to obtain serum The procedure was as described in example 3.
- Fig-5 Summary: The intramuscular application of Proteoliposome (AFPLl) or Cochleate (AFCoI) requires at least two doses to induce significant systemic specific IgG responses.
- Example 8 The intranasal route requires three doses with Cochleate (AFCoI) or Proteoliposome (AFPLl) to induce high levels of specific IgA in saliva in mice.
- Immunization Protocol Balb / c mice were immunized with AFPLl or AFCoI intranasally using three immunization schedules of one, two and three doses respectively of each formulation per group. Each dose was administered at an interval of 7 days at a concentration of 50 ⁇ g in 25 ⁇ L per animal, 12.5 ⁇ L per nostril as described in example 5.
- Both AFCoI and AFPLl applied by the nasal route require two doses to induce specific positive IgA responses in saliva. However, with three doses, superior responses are obtained. In all cases, the AFCoI induced higher responses than the AFPLl.
- Example 9 The intranasal route requires three doses with Cochleate (AFCoI) or Proteoliposome (AFPLl) to induce high levels of serum specific IgG in mice.
- AFCoI Cochleate
- AFPLl Proteoliposome
- mice were immunized with AFPLl or AFCoI intranasally using three immunization schedules of one, two and three doses respectively of each formulation per group. Each dose was administered at an interval of 7 days at a concentration of 50 ⁇ g in 25 ⁇ L per animal, 12.5 ⁇ L per nostril as described in example 5.
- AFPLl Simultaneous intramuscular proteoliposome (AFPLl) (STVS) induces higher specific IgG responses than three doses of nasal AFCoI and similar to two doses of parenteral AFPLl, maintaining similar proportions of serum IgG subclasses in mice.
- mice were distributed in three immunized groups and one control.
- a first group were immunized with three doses (0, 7, 14 days) of APCoI intranasally at a concentration of 50 ⁇ g in 25 ⁇ L per animal, 12.5 ⁇ L per nostril.
- a second group immunized with two doses (0.14 days) of AFPLl intramuscularly at a concentration of 12.5 ⁇ g in 50 ⁇ L per animal.
- the third group was immunized with AFCoI (100 ⁇ g in 25 ⁇ L, 12.5 ⁇ L for each nostril) intranasally and simultaneously with AFPLl (STVS) (12.5 ⁇ g in 50 ⁇ L) intramuscularly.
- AFCoI 100 ⁇ g in 25 ⁇ L, 12.5 ⁇ L for each nostril
- Coating lamp solution Na 2 CO 3 11 mM, NaHCO 3 35 mM (pH 9.6)
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- Example 11 Immunization of a dose of simultaneous intramuscular Cochleate (AFCoI) and simultaneous intramuscular Proteoliposome (AFPLl) (STVS) induces high levels of anti PL IgA in saliva, feces and vaginal lavage in immunized mice.
- AFCoI simultaneous intramuscular Cochleate
- AFPLl simultaneous intramuscular Proteoliposome
- mice Female Balb / c mice were distributed in three immunized groups and one control. A first group was immunized with three doses (0, 7, 14 days) of AFCoI intranasally at a concentration of 50 ⁇ g in 25 ⁇ L per animal, 12.5 ⁇ L per nostril. A second group was immunized with two doses (0.14 days) of AFPLl intramuscularly at a concentration of 12.5 ⁇ g in 50 ⁇ L per animal. The third group was immunized with a dose of AFCoI (100 ⁇ g in 25 ⁇ L) intranasally and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- AFCoI 100 ⁇ g in 25 ⁇ L
- AFPLl 12.5 ⁇ g in 50 ⁇ L
- Saliva extraction and processing method in this example saliva extraction was performed 7 and 14 days after immunization and the rest was performed as indicated in example 4.
- Stool extraction and processing method stool extraction was performed 14 days after the last dose. Three fecal pellets were collected per animal. The feces were weighed by subtracting the value of the weight of the vials. These pellets were resuspended in a solution of PBS with protease inhibitors (1 mM PMSF and 5 ⁇ g of Aprotinin per mL), using a dilution of 20 ⁇ L per mg of feces. The resuspended samples were vigorously agitated using a magnetic stirrer (vorter), discarding the insoluble material by centrifugation (40,000 rpm, 20 minutes at 4 ° C) and storing the supernatant for further analysis.
- a magnetic stirrer vorter
- vaginal lavage samples were collected 21 days after the last dose as well as serum. These were obtained by applying 100 ⁇ L of sterile PBS into the animal's vagina, aspirating the vaginal wash and collecting it in vials. They were then centrifuged at 14000 rpm, 15 minutes at 4 ° C, keeping the supernatant for further analysis.
- Example 12 Immunization of a dose of intranasal Ovalbumin (AFCol-Ova) Cochleate and simultaneous intramuscular Ova (AFPLl-Ova) Proteoliposome (STVS) induces high levels of anti-Ova IgG in mice.
- AFCol-Ova intranasal Ovalbumin
- AFPLl-Ova simultaneous intramuscular Ova
- STVS Proteoliposome
- mice were distributed in four immunized groups and one control.
- a first group was immunized with three doses (0, 7, 14 days) of AFCol-Ova intranasally at a concentration of 50 ⁇ g / 20 ⁇ g in 25 ⁇ L per animal, 12.5 ⁇ L per nostril.
- a second group was immunized with two doses (0.14 days) of AFPLl-Ova intramuscularly at a concentration of 12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L per animal.
- the third group was immunized with a dose of AFCol-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) intranasally and a simultaneous dose of AFPLl-Ova (12.5 ⁇ g / 10 ⁇ g in
- the fourth group was immunized with two doses (0.14 days) of Ova intramuscularly at a concentration of 10 ⁇ g in 50 ⁇ L per animal.
- Coating buffer solution 11 mM Na2CO3, 35 mM NaHCO3 (pH 9.6) Phosphate Buffered Saline (SSTF) 0.15 M (pH 7.2) Blocking solution (SSTF / 1% SAB): 0.15 M SSTF (pH 7.2 ), 1% Bovine Seroalbumine (w / v)
- wash solution (SSTF, Tween 20 0.1%): SSTF, Tween 20 0.1% (v / v), pH 7.4) Sample dilution solution (SSTF, SAB 1%, Tween 20 0.1%) Anti-IgG mouse conjugated to peroxidase (Sigma, St. Louis, MO, USA) Substrate buffer solution, STS (52 mM Na2HPO4 and 25 mM citric acid (pH 5.6))
- the sera to be evaluated were diluted 1: 100 in Sample dilution solution. 100 ⁇ L / well are applied in duplicate of the dilutions of the individual sera and the reference serum and incubate 2 h at 37 ° C.
- the reaction is stopped by adding 50 ⁇ L of a stop solution.
- the absorbance measurement (OD) is performed at a reading of 492 nm in a microplate reader (Titertek, Multiskan Plus).
- AFCol-Ova Intranasal
- AFPLl-Ova simultaneous intramuscular Ova
- STVS Proteoliposome
- mice Balb / c mice were distributed in five immunized groups and one control. A first and a second group were immunized with three (0, 7, 14 days) and 2
- AFPLl-Ova intramuscularly at a concentration of 12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L per animal.
- the fourth group was immunized with AFCol-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) intranasally and simultaneously AFPLl-Ova (STVS) (12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly .
- STVS AFPLl-Ova
- Saliva Extraction and Processing Method In this example saliva extraction was performed 7 and 14 days after immunization the rest was performed as indicated in example 4.
- Coating buffer solution 11 mM Na2CO3, 35 mM NaHCO3 (pH 9.6) Phosphate Buffered Saline (SSTF) 0.15 M (pH 7.2)
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- Washing solution (SSTF, Tween 20 0.1%): SSTF, Tween 20 0.1% (v / v), pH 7.4)
- Substrate buffer solution STS (52 mM Na2HPO4 and 25 mM citric acid (pH 5.6))
- Stop Solution H2SO42 M. Standard Antibody Saliva: As an internal antibody standard, for the testing of
- IgA anti-PL a curve made with saliva samples from hyper immune mice was used.
- the saliva to be evaluated is diluted 1: 2 in Sample dilution solution. 100 ⁇ L / well is applied in duplicate of the dilutions of the individual sera and the reference serum and incubated 2 h at 37 ° C.
- a second conjugate (streptavidin peroxidase) is added in a 1: 2000 dilution in Sample Dilution Solution and incubated 30 min at 37 ° C
- the reaction is stopped by adding 50 ⁇ L of a stop solution.
- intranasal AFCoI -Ova and intramuscular AFPLl -Ova induces significant anti-Ova IgA responses in saliva. These are superior to those induced by two doses of AFCoI -Ova or 3 doses of intranasal Ova and not induced by two doses of
- Cochleate (AFCoI) and Proteoliposome (AFPLl) can be efficiently used by both immunization routes (intranasal and intramuscular) in the unitemporal strategy.
- mice were distributed in four immunized groups and one control.
- a first group was immunized with a dose of AFCoI (100 ⁇ g in 25 ⁇ L) intranasally and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time
- the second with a dose of AFCoI (100 ⁇ g in 25 ⁇ L) intranasally and a dose of AFCoI (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time
- the third with a dose of AFPLl (100 ⁇ g in 25 ⁇ L) intranasally and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- As a positive control a group with three doses (0, 7, 14 days) of AFCoI intranasally at a concentration of 50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostri
- Cochleate (AFCoI) and Proteoliposome (AFPLl) containing Ovalbumin (AFCol-Ova and AFPLl-Ova) can be efficiently used by both immunization routes (Intranasal and Intramuscular) in the unitemporal strategy.
- mice were distributed in five immunized groups and one control.
- a first group was immunized with a dose of AFCol-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and a dose of AFPLl-Ova (12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- AFCol-Ova 100 ⁇ g / 50 ⁇ g in 25 ⁇ L
- AFPLl-Ova 12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L
- the second group was immunized with a dose of AFCoI-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and a dose of AFCol-Ova (12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly in a single time and the third with a dose of AFPLl-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and a dose of AFPLl-Ova (12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- a group with three doses (0, 7, 14 days) of AFCol-Ova was used intranasally at a concentration of 50 ⁇ g / 25 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril and another with three intranasal Ova dose (25 ⁇ g / 25 ⁇ L) per animal
- the Unitemporal Vaccination Strategy also includes the administration of a dose of AFCoI by other mucosal routes (oral or sublingual) and AFPLl intramuscularly, respectively at the same time (STVS) inducing high levels of specific IgA in feces and vaginal lavage .
- mice were distributed in six immunized groups and one control. The first three groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L), respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- AFCoI intranasally 100 ⁇ g in 25 ⁇ L
- IG oral
- Sl sublingual
- AFPLl AFPLl (12.5 ⁇ g in 50 ⁇ L
- IM intramuscularly
- Detection of anti PL IgA by ELISA Proceed as described in Example 4. Conclusion of the results: a dose of Intramuscular AFPLl combined with a dose of oral or sublingual AFCoI in a single time (STVS) induces high levels of anti IgA PL in feces and vaginal lavage, compared with those induced by the three doses of AFCoI administered orally or sublingually (Fig. 17 and 18).
- Example 17 Unitemporal administration of a dose of AFCoI orally or sublingually and AFPLl intramuscularly respectively (STVS) induces high levels of serum-specific IgG in mice.
- mice were distributed in six immunized groups and one control. The first three groups were immunized with a dose of AFCo.l intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L) , respectively and one dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- AFCo.l intranasally 100 ⁇ g in 25 ⁇ L
- IG oral
- Sl sublingual
- the remaining three groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal), IG (100 ⁇ g in 200 ⁇ L) or Sl (50 ⁇ g in 25 ⁇ L per animal), respectively.
- a dose of intramuscular AFPLl combined with a dose of oral or sublingual AFCoI in a single time induces as high levels of serum anti PL IgG, as those induced by the three doses of oral or sublingual administered AFCoI (Fig. 19).
- Example 18 In the strategy of Unitemporal Vaccination the administration of AFCoI by several mucosal routes at the same time in combination and AFPLl by intramuscular route at the same time (STVS) induces high levels of specific IgA in feces, in mice.
- Immunization Protocol Balb / c mice were distributed in thirteen immunized groups and one control.
- the first three groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L), respectively and one dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- AFCoI intranasally 100 ⁇ g in 25 ⁇ L
- IG oral
- Sl sublingual
- AFPLl intramuscularly
- Three other groups were immunized with AFCoI by combining two of the previous mucosal pathways and one dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) by IM in a single time, IN-IG-IM, IN-Sl-IM or IG-Sl- IM.
- the remaining three groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal), IG (100 ⁇ g in 2O ⁇ ' ⁇ L) or Sl (50 ⁇ g in 25 ⁇ L per animal), respectively.
- Detection of anti PL IgA by ELISA Proceed as described in Example 4. Conclusion of the results: one dose of intramuscular AFPLl at the same time (STVS) with one dose of AFCoI by several combined mucosal induces high levels of anti IgA PL in feces and vaginal lavage, compared with those induced by the three doses of AFCoI administered intranasally, orally or sublingually. These responses are synergized by the simultaneous application of two mucosal pathways (Fig. 20-22).
- Example 19 Immunization with diphtheria toxoid (TT) tetanus toxoid (TD) or cellular pertussis (P), co-administered with the Cocleate intranasally, sublingually and orally, respectively simultaneously with the DPT vaccine (absorbed in alumina ) added intramuscularly induces significant systemic IgG responses against all antigens.
- Immunization Protocol Balb / c mice were distributed in seven immunized groups and one control.
- the first three groups were immunized with AFCol + TT (100 ⁇ g / 10 LF (flocculation units) in 25 ⁇ L) intranasally (IN), AFCoI-TD (100 ⁇ g / 25 LF in 25 ⁇ L) sublingually (Sl ) or AFCoI-P (100 ⁇ g / 16 UO (opacity units) in 25 ⁇ L) orally (IG) and simultaneously intramuscular DPT (IM).
- Groups 4, 5 and 6 were immunized with 3 doses in simulated concentrations of AFCol + TT, AFCoI-TD or AFCoI-P by IN, SL or IG routes respectively.
- Another group was immunized with two doses of IM DPT.
- TT anti-Tetanus Toxoid
- ELISA Reagents and Solutions: Tetanus Toxoid: ATPE- Lot 8005 Finlay Institute, c (808LF / mL)
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- the sera to be evaluated were diluted 1: 100 in Sample dilution solution. 100 ⁇ L / well are applied in duplicate of the dilutions of the individual sera and the reference serum and incubate 2 h at 37 ° C.
- Diphtheria Toxoid ADPE- Lot 8001 Finlay Institute, c (1200LF / mL) Coating buffer solution (STR): Na 2 CO 3 11 raM, NaHCO 3 35 mM (pH 9.6)
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- Substrate buffer solution STS (52 mM Na 2 HPO 4 and 25 mM citric acid (pH 5.6))
- the sera to be evaluated were diluted 1: 100 in Sample dilution solution. 100 ⁇ L / well are applied in duplicate of the dilutions of the individual sera and the reference serum and incubate 2 h at 37 ° C. • Wash three times with Wash Solution • 100 ⁇ L / well of the Anti IgG conjugate diluted 1: 2000 in solution of
- PC Cellular Pertussis
- Blocking solution 1% SSTF / SAB: 0.15 M SSTF (pH 7.2), 1% Bovine Seroalbumine
- the sera to be evaluated were diluted 1: 100 in Sample dilution solution. 100 ⁇ L / well are applied in duplicate of the dilutions of the individual sera and the reference serum and incubate 2 h at 37 ° C. • Wash three times with Wash Solution
- Example 20 The single dose immunization with the intramuscular Cochleate (AFCoI) and the simultaneous intramuscular Proteoliposome (AFPLl) (STVS) induces demonstrated memory response after a booster dose administered at 4 months after immunization.
- AFCoI intramuscular Cochleate
- AFPLl simultaneous intramuscular Proteoliposome
- mice were distributed in two immunized groups and one control.
- a first group immunized with two doses (0.14 days) of AFPLl intramuscularly at a concentration of 12.5 ⁇ g in 50 ⁇ L per animal.
- the second group was immunized with a dose of AFCoI (50 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) by route intranasally and simultaneously (STVS) AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly.
- AFCoI 50 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril
- Method of Extraction and processing of blood to obtain serum The procedure was as described in example 3, adding that the extractions were performed at 21 days, 70, 90 and 120 days after the last dose administered, as well as at 21 days after the challenge.
- the unitemporal immunization strategy not only induces responses at the effector level but also induces a good memory response appreciated after administering a booster dose 4 months after immunization.
- Example 22 Immunization with the Cochleate containing Ova (AFCol-Ova) Intranasal and the simultaneous intramuscular Ova (AFPLl-Ova) Proteoliposome (STVS) induces anti-Ova memory response after a dose of Ova booster administered at 4 months after immunization
- mice were distributed in three immunized groups and one control.
- a first group immunized with two doses (0.14 days) of AFPLl-Ova intramuscularly at a concentration of 12.5 ⁇ g / lO ⁇ g at 50 ⁇ L per animal.
- the second group was immunized with a dose of AFCol-Ova (50 ⁇ g / 25 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) intranasally and simultaneously (STVS) a dose of AFPLl (12.5 ⁇ g / lO ⁇ g in 50 ⁇ L) intramuscularly.
- a third group immunized with two doses Ova (10 ⁇ g in 50 ⁇ L) intramuscular.
- Ova 10 ⁇ g in 50 ⁇ L
- an intranasal challenge was performed with 25 ⁇ g of Ova included in AFCoI in 25 ⁇ L, 12.5 ⁇ L for each nostril in groups 1 and 2 or only intramuscular Ova in group
- the unitemporal immunization strategy with Ova as an incorporated antigen not only induces responses at the effector level but also induces an anti-Ova memory response appreciated after administering an intranasal Ova booster dose at 4 months after immunization.
- the unitemporal immunization strategy with Ova as an incorporated antigen not only induces responses at the effector level but also induces an anti-Ova memory response appreciated after administering an intranasal Ova booster dose at 4 months after immunization.
- Example 23 The Unitemporal Immunization Strategy also works using other mucosal adjuvants such as cholera toxin (CT).
- CT cholera toxin
- mice were distributed in two immunized groups and one control.
- a first group was immunized with a dose of APCol-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of AFPLl-Ova (25 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- a second group was immunized with a dose of CT-Ova (5 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of CT-Ova (5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- Method of Extraction and processing of blood to obtain the serum The procedure was as described in example 3.
- Method of Extraction and processing of vaginal lavage The procedure was carried out as described in example 11.
- Detection of anti-Ova IgG by ELISA Proceed as described in example 14.
- Detection of anti-Ova IgA by ELISA Proceed as described in example 15.
- FIG. 1 Anti-PL IgG response in serum induced by AFCoI, AFPLl or VA-MENGOC-BC ® administered intramuscularly.
- Balb / c mice were immunized with 2 doses (0, 14 days) of AFCoI, AFPLl or VA-MENGOC-BC ® Intramuscularly (12.5 ⁇ g / 50 ⁇ L).
- the serum samples extracted 21 days after the last dose were used for the evaluation of anti PL IgG levels. The determination was made through a
- IgG ELISA anti PL The figure shows the mean and standard deviation of the mathematical relationship of the values (U / mL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test
- FIG. 1 Anti-PLA IgA response in saliva induced by AFCoI, AFPLl or VA-MENGOC-BC ® administered intramuscularly.
- Balb / c mice were immunized with two doses (0.14 days) of AFCoI, AFPLl or VA-MENGOC-BC ® Intramuscularly (12.5 ⁇ g / 50 ⁇ L).
- For the evaluation of anti PL IgA levels saliva samples extracted 7 days after the last immunized dose were used. The determination was made by an anti PLA IgA ELISA.
- the figure shows the mean and standard deviation of the mathematical relationship of the values (UAJmL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 3 Anti-PLA IgA response in saliva induced by AFCoI or AFPLl administered intranasally.
- Balb / c mice were immunized with three doses (0, 7, 14 days) of AFCoI or AFPLl intranasally (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril).
- saliva samples extracted 7 days after the last dose were used. The determination was made by an anti PLA IgA ELISA.
- the figure shows the mean and standard deviation of the mathematical relationship of the values (AU / mL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- Anti-PL IgG response in serum induced by AFCoI or AFPLl administered intranasally Balb / c mice were immunized with three doses (0, 7, 14 days) of AFCoI or AFPLl intranasally (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril).
- AFCoI or AFPLl intranasally 50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril.
- the determination was made by means of an anti PL IgG ELISA.
- the graph shows the mean and standard deviation of the mathematical relationship of the values (U / mL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 1 Serum anti PL IgG response induced by one and two doses of AFCoI or AFPH administered intramuscularly.
- Balb / c mice were immunized with one or two doses of AFCoI or AFPLl Intramuscularly (12.5 ⁇ g / 50 ⁇ L).
- the serum samples extracted 21 days after the last dose were used for the evaluation of anti PL IgG levels.
- the determination was made by an anti PL IgG ELISA.
- the figure shows the mean and standard deviation of the mathematical relationship of the values (U / mL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 6 Anti PLA IgA response in saliva induced by one, two or three doses of AFCoI or AFPLl administered intranasally.
- Balb / c mice were immunized with one, two or three doses of AFCoI or AFPLl intranasally (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril).
- saliva samples extracted 7 days after the last dose were used. The determination was made by an anti PLA IgA ELISA.
- the figure shows the mean and standard deviation of the mathematical relationship of the values (AU / mL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- AFCoI or AFPLl administered intranasally Balb / c mice were immunized with one, two or three doses of AFCoI or AFPLl intranasally (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril).
- anti PL IgG levels serum samples taken 21 days after the last dose. The determination was made by an anti PL IgG ELISA.
- the figure shows the means and standard deviation of the mathematical relationship of the values (LVmL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 8 Serum anti PL IgG response induced by unitemporal immunization (STVS) of Intranasal AFCoI and Intramuscular AFPLl.
- Balb / c mice were distributed in three immunized groups and one as a control.
- a first group immunized with three doses (0, 7, 14 days) of AFCoI (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril) intranasally (IN).
- a second group immunized with two doses (0, 14 days) of AFPLl (12.5 ⁇ g / 50 ⁇ L per animal) Intramuscularly (IM).
- FIG. 9 Response of IgGl and IgG2a anti PL in serum induced by unitemporal immunization (STVS) of Intranasal AFCoI and Intramuscular AFPLl.
- Balb / c mice were distributed in three immunized groups and one as a control.
- a first group immunized with three doses (0, 7, 14 days) of AFCoI (50 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril) intranasally (IN).
- a second group immunized with two doses (0.14 days) of AFPLl (12.5 ⁇ g / 50 ⁇ L per animal) Intramuscularly (IM).
- AFPLl 12.5 ⁇ g / 50 ⁇ L
- AFCoI 100 ⁇ g / 25 ⁇ L
- mice were distributed in four immunized groups and one as a control.
- a first group immunized with three doses (0, 7, 14 days) of AFCoI (50 ⁇ g / 25 ⁇ L per animal) by Intranasal route (IN).
- IM intramuscularly
- the figure shows the mean and standard deviation of the mathematical relationship of the values (UA / mL) of the saliva extracted at 7 days for the AFCoI, AFPLl groups and at 14 days for the STVS group in 3 independent experiments in which The answers were the maximum.
- Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 11 Anti-PLA IgA response in feces, induced by simultaneous immunization of Intramuscular AFPLl and Intranasal AFCoI in a single time (STVS).
- Balb / c mice were distributed in three immunized groups and one control.
- a first group was immunized with a dose of intramuscular (IM) AFPLl (12.5 ⁇ g / 50 ⁇ L) and intranasal (IN) AFCoI (100 ⁇ g / 25 ⁇ L) in a single time and a second group immunized with three doses (0, 7 , 14 days) of AFCoI (50 ⁇ g / 25 ⁇ L per animal) via IN.
- IM intramuscular
- IN intranasal
- Balb / c mice were distributed in three immunized groups and one control.
- IM intramuscular
- AFCoI 100 ⁇ g / 25 ⁇ L
- IN route intranasal
- FIG. 13 Serum anti Ova IgG response induced by unitemporal immunization (STVS) of Intranasal AFCol-Ova and Intramuscular AFPL-Ova.
- Balb / c mice were distributed in four immunized groups and one as a control.
- a first group immunized with three doses (0, 7, 14 days) of AFCol-Ova (50 ⁇ g / 25 ⁇ g / 25 ⁇ L per animal, 12.5 ⁇ L per nostril) intranasally (IN).
- a second group immunized with two doses (0.14 days) of AFPLl-Ova (12.5 ⁇ g / 10 ⁇ g / 50 ⁇ L per animal) intramuscularly (IM).
- Ova 10 ⁇ g / 50 ⁇ L per animal
- FIG. 14 Anti Ova IgA response in saliva induced by unitemporal immunization (STVS) of Intranasal AFCoI and Intramuscular AFPLl.
- STVS unitemporal immunization
- Balb / c mice were distributed in four immunized groups and one as a control.
- IM intramuscularly
- FIG. 15 Anti PL IgG response induced by simultaneous immunization of intramuscular AFCoI and intranasal AFCoI in a single time or intramuscular AFPLl and intranasal AFPLl in a single time (homologous STVS).
- Balb / c mice were distributed in four immunized groups and one control.
- a first group was immunized with a dose of AFCoI (lOO ⁇ g in 25 ⁇ L) intranasally (IN) and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time, the second with a dose of AFCoI (100 ⁇ g in 25 ⁇ L) by IN route and a dose of AFCoI (12.5 ⁇ g in 50 ⁇ L) by IM in a single time and the third with a dose of AFPLl (100 ⁇ g in 25 ⁇ L) by IN route and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly in a single time.
- FIG. 16 Anti Ova IgG response induced by simultaneous immunization of Intramuscular AFCol-Ova and Intranasal AFCol-Ova in a single time or Intramuscular AFPLl-Ova and Intranasal AFPLl-Ova in a single time (STVS homologue).
- Balb / c mice were distributed in six immunized groups and one control.
- a first group immunized with a dose of AFCol-Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally (IN) and a dose of AFPLl-Ova (12.5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly (IM) In a single time.
- serum samples taken 21 days after the last dose were used for the evaluation of anti-Ova IgG levels.
- FIG. 1 IgA response in feces induced by unitemporal administration of one dose of AFCoI orally or sublingually and AFPLl intramuscularly, respectively at the same time (STVS).
- Balb / c mice were distributed in six immunized groups and one control. The first three groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L) respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- the remaining three groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal), IG (100 ⁇ g in 200 ⁇ L) or Sl (50 ⁇ g in 25 ⁇ L per animal), respectively .
- AFCoI IN 50 ⁇ g in 25 ⁇ L per animal
- IG 100 ⁇ g in 200 ⁇ L
- Sl 50 ⁇ g in 25 ⁇ L per animal
- FIG. 18 IgA response in vaginal lavage induced by unitemporal administration of one dose of AFCoI orally or sublingually and AFPLl intramuscularly, respectively at the same time (STVS).
- Balb / c mice were distributed in six immunized groups and one control. The first three groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L) respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- the remaining three groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal), IG (100 ⁇ g in 200 ⁇ L) or Sl (50 ⁇ g in 25 ⁇ L per animal), respectively .
- AFCoI IN 50 ⁇ g in 25 ⁇ L per animal
- IG 100 ⁇ g in 200 ⁇ L
- Sl 50 ⁇ g in 25 ⁇ L per animal
- FIG. 19 Serum IgG response induced by unitemporal administration of one dose of AFCoI orally or sublingually and AFPLl intramuscularly at the same time (STVS).
- Balb / c mice were distributed in six immunized groups and one control. The first three groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L), oral (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L), respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- IM intramuscularly
- the remaining three groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal), IG (100 ⁇ g in 200 ⁇ L) or Sl (50 ⁇ g in 25 ⁇ L per animal), respectively .
- the serum samples extracted 21 days after the last dose were used for the evaluation of anti PL IgG levels.
- the determination was made by an anti PL IgG ELISA.
- the figure shows the means and standard deviations of the mathematical relationship of the values (LVmL) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 20 Anti-PLA IgA response in feces, induced by simultaneous immunization of intramuscular AFPLl and intranasal-oral AFCoI combined in a single time
- mice Balb / c mice were distributed in five immunized groups and one control. The first two groups were immunized with a dose of AFCoI intranasally (IN) (100 ⁇ g in 25 ⁇ L) or oral (IG) (100 ⁇ g in 200 ⁇ L), respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time. Another group immunized with a dose of AFCoI by IN route (100 ⁇ g in 25 ⁇ L) and IG (100 ⁇ g in 200 ⁇ L) in combination and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) by IM route in a single time.
- AFCoI intranasally 100 ⁇ g in 25 ⁇ L
- IG oral
- AFPLl intramuscularly
- Another group immunized with a dose of AFCoI by IN route (100 ⁇ g in 25 ⁇ L) and IG (100
- FIG. 21 Anti-PLA IgA response in feces, induced by the simultaneous immunization of Intramuscular AFPLl and intranasal-sublingual AFCoI combined in a single time (STVS).
- Balb / c mice were distributed in five immunized groups and one control. The first two groups were immunized with a dose of AFCoI intranasally (ESi) (100 ⁇ g in 25 ⁇ L) or sublingual (Sl) (100 ⁇ g in 200 ⁇ L), respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- ESi AFCoI intranasally
- Sl sublingual
- AFPLl AFPLl (12.5 ⁇ g in 50 ⁇ L
- IM intramuscularly
- Two remaining groups were immunized with three doses (0, 7, 14) of AFCoI IN (50 ⁇ g in 25 ⁇ L per animal) or sublingual (50 ⁇ g in 25 ⁇ L), respectively.
- IgA levels against PL stool samples taken 14 days after the last immunized dose were used. The determination was made by means of an IgA ELISA against PL.
- the graph shows the means and standard deviations of the mathematical relationship of the values (UAJmL) of IgA in feces extracted at 21 days in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG 22 Anti-PLA IgA response in feces, induced by simultaneous immunization of intramuscular AFPL1 and oral-sublingual AFCoI combined in a single time (STVS).
- Balb / c mice were distributed in five immunized groups and one control. The first two groups were immunized with a dose of AFCoI orally (IG) (100 ⁇ g in 200 ⁇ L) or sublingual (Sl) (100 ⁇ g in 25 ⁇ L), respectively and a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) in a single time.
- IG AFCoI orally
- Sl sublingual
- AFPLl AFPLl (12.5 ⁇ g in 50 ⁇ L
- IM intramuscularly
- the remaining two groups were immunized with three doses (0, 7, 14) of AFCoI Sl (50 ⁇ g in 25 ⁇ L per animal) or IG (100 ⁇ g in 200 ⁇ L).
- IG 100 ⁇ g in 200 ⁇ L
- the graph shows the means and standard deviations of the mathematical relationship of the values (UA / mL) of fecal IgA extracted at 21 days in 3 independent experiments.
- FIG 23 Anti-PL memory response induced by simultaneous immunization of intranasal AFCoI and intramuscular AFPLl (STVS).
- Balb / c mice were distributed in two immunized groups and one control.
- a first group immunized with two doses (0.14 days) of AFPLl intramuscularly (IM) at a concentration of 12.5 ⁇ g in 50 ⁇ L per animal.
- the second group was immunized with a dose of AFCoI (50 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) intranasally (IN) and simultaneously a dose of AFPLl (12.5 ⁇ g in 50 ⁇ L) intramuscularly (IM) ( STVS).
- an intranasal challenge was performed with 50 ⁇ g of each antigen in 25 ⁇ L, 12.5 ⁇ L per nostril.
- serum samples taken 21, 70, 90 and 120 days after the last immunization dose were used, as well as 14 and 21 days after the challenge.
- the determination was made by an anti PL IgG ELISA.
- the figure shows the mean and standard deviation of the mathematical relationship of the values (OD) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 24 Anti-Ova memory response induced by the simultaneous immunization of intranasal AFCol-Ova and intramuscular AFPL-Ova (STVS).
- Balb / c mice were distributed in three immunized groups and one as a control.
- a first group immunized with two doses (0.14 days) of AFPLl-Ova intramuscularly (IM) at a concentration of 12.5 ⁇ g / lO ⁇ g at 50 ⁇ L per animal.
- IM AFPLl-Ova intramuscularly
- the second group was immunized with a dose of AFCol-Ova (50 ⁇ g / 25 ⁇ g in 25 ⁇ L, 12.5 ⁇ L per nostril) intranasally (IN) and simultaneously (STVS) a dose of AFPLl (12.5 ⁇ g / lO ⁇ g in 50 ⁇ L) via IM.
- a third group immunized with two doses Ova (10 ⁇ g in 50 ⁇ L) IM.
- a challenge was performed intranasally with AFCol-Ova (50 ⁇ g / 25 ⁇ g) in 25 ⁇ L, 12.5 ⁇ L per nostril.
- a first group was immunized with a dose of APCoI -Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of AFPLl -Ova (25 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- a second group was immunized with a dose of CT-Ova (5 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of CT-Ova (5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- anti-Ova IgG levels serum samples taken 21 days after the last dose were used. The determination was made by an anti-Ova IgG ELISA. The figure shows the mean and standard deviation of the mathematical relationship of the values (OD) of 2 determinations in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 26 Anti Ova IgA response in vaginal lavage induced by unitemporal administration of a dose of CT-Ova intranasally and CT-Ova intramuscularly at the same time (STVS).
- Balb / c mice were distributed in two immunized groups and one control.
- a first group was immunized with a dose of AFCoI -Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of AFPLl -Ova (25 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- a second group was immunized with a dose of CT-Ova (5 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of CT-Ova (5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- CT-Ova 5 ⁇ g / 50 ⁇ g in 25 ⁇ L
- CT-Ova 5 ⁇ g / 10 ⁇ g in 50 ⁇ L
- intramuscularly For the evaluation of anti-Ova IgA levels, vaginal lavage samples taken at 21 days after the last dose were used. The determination was made using an anti-Ova IgA ELISA. The figure shows the mean and standard deviation of the mathematical relationship of the values (OD) of the vaginal lavage extracted at 21 days in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
- FIG. 27 Anti-Ova IgA response in feces induced by the unitemporal administration of a dose of CT-Ova intranasally and CT-Ova intramuscularly at the same time (STVS).
- Balb / c mice were distributed in two immunized groups and one control.
- a first group was immunized with a dose of AFCoI -Ova (100 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of AFPLl-Ova (25 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- a second group was immunized with a dose of CT-Ova (5 ⁇ g / 50 ⁇ g in 25 ⁇ L) intranasally and simultaneously a dose of CT-Ova (5 ⁇ g / 10 ⁇ g in 50 ⁇ L) intramuscularly.
- a dose of CT-Ova 5 ⁇ g / 50 ⁇ g in 25 ⁇ L
- a dose of CT-Ova 5 ⁇ g / 10 ⁇ g in 50 ⁇ L
- intramuscularly For the evaluation of the levels of anti-Ova IgA, stool samples taken 14 days after the last dose were used. The determination was made using an anti-Ova IgA ELISA. The figure shows the mean and standard deviation of the mathematical relationship of the values (OD) of the feces extracted at 14 days in 3 independent experiments. Different p denote significant differences according to Tukey test (p ⁇ 0.05).
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009317725A AU2009317725A1 (en) | 2008-11-19 | 2009-11-19 | Single-time vaccines |
US13/130,146 US20110256214A1 (en) | 2008-11-19 | 2009-11-19 | Single-time vaccines |
CN2009801547982A CN102497879A (zh) | 2008-11-19 | 2009-11-19 | 单时疫苗 |
BRPI0921578A BRPI0921578A2 (pt) | 2008-11-19 | 2009-11-19 | vacinas unitemporais |
EP09827196.8A EP2359850A4 (en) | 2008-11-19 | 2009-11-19 | ONCE-VACCINATIONS |
CA2744048A CA2744048A1 (en) | 2008-11-19 | 2009-11-19 | Single-time vaccines |
ZA2011/03645A ZA201103645B (en) | 2008-11-19 | 2011-05-17 | Single-time vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CUCU/2008/215 | 2008-11-19 | ||
CU20080215A CU20080215A7 (es) | 2008-11-19 | 2008-11-19 | Vacunas unitemporales |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010057447A1 true WO2010057447A1 (es) | 2010-05-27 |
Family
ID=42197852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2009/000008 WO2010057447A1 (es) | 2008-11-19 | 2009-11-19 | Vacunas unitemporales |
Country Status (9)
Country | Link |
---|---|
US (1) | US20110256214A1 (es) |
EP (1) | EP2359850A4 (es) |
CN (1) | CN102497879A (es) |
AU (1) | AU2009317725A1 (es) |
BR (1) | BRPI0921578A2 (es) |
CA (1) | CA2744048A1 (es) |
CU (1) | CU20080215A7 (es) |
WO (1) | WO2010057447A1 (es) |
ZA (1) | ZA201103645B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200345825A1 (en) * | 2017-12-26 | 2020-11-05 | Universidad De Chile | Formulation of fish vaccine based on lipidic nanovesicles, in particular, a proteoliposome or cochleate, with activity against the salmonid rickettsial syndrome (srs) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20100083A7 (es) | 2010-05-05 | 2012-06-21 | Inst Finlay | Tolerogenos adyuvados como vacuna de malaria |
CU20110202A7 (es) | 2011-11-02 | 2013-12-27 | Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas | Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes |
DK2879502T3 (en) | 2012-07-30 | 2018-10-15 | Matinas Biopharma Nanotechnologies Inc | COCHLEATES PREPARED WITH SOYAPHOSPHATIDYLSERINE |
WO2020187255A1 (en) | 2019-03-20 | 2020-09-24 | Advagene Biopharma Co., Ltd. | Method of modulating mucosal immunogenicity |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597572A (en) | 1987-07-30 | 1997-01-28 | Centro Nacional De Biopreparados | Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method |
WO2002080648A2 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
WO2003094964A1 (es) | 2002-05-08 | 2003-11-20 | Instituto Finlay, Centro De Investigación- Pruducción De Vacunas Y Sueros | Composición vacunal contra las alergias, método para su obtención y empleo en el tratamiento de las mismas |
WO2004047805A1 (es) | 2002-11-27 | 2004-06-10 | Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. | Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios. |
EP1716866A1 (en) | 2003-12-30 | 2006-11-02 | Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros | Proteoliposomes and derivatives thereof as cytotoxic response-inducing adjuvants and resulting formulations |
EP1878424A2 (en) | 1999-09-24 | 2008-01-16 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557931A (en) * | 1982-12-02 | 1985-12-10 | Regents Of The University Of California | Antigenic compositions and methods for using same |
-
2008
- 2008-11-19 CU CU20080215A patent/CU20080215A7/es unknown
-
2009
- 2009-11-19 BR BRPI0921578A patent/BRPI0921578A2/pt not_active IP Right Cessation
- 2009-11-19 US US13/130,146 patent/US20110256214A1/en not_active Abandoned
- 2009-11-19 CN CN2009801547982A patent/CN102497879A/zh active Pending
- 2009-11-19 AU AU2009317725A patent/AU2009317725A1/en not_active Abandoned
- 2009-11-19 EP EP09827196.8A patent/EP2359850A4/en not_active Withdrawn
- 2009-11-19 CA CA2744048A patent/CA2744048A1/en not_active Abandoned
- 2009-11-19 WO PCT/CU2009/000008 patent/WO2010057447A1/es active Application Filing
-
2011
- 2011-05-17 ZA ZA2011/03645A patent/ZA201103645B/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597572A (en) | 1987-07-30 | 1997-01-28 | Centro Nacional De Biopreparados | Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method |
EP1878424A2 (en) | 1999-09-24 | 2008-01-16 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
WO2002080648A2 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
WO2003094964A1 (es) | 2002-05-08 | 2003-11-20 | Instituto Finlay, Centro De Investigación- Pruducción De Vacunas Y Sueros | Composición vacunal contra las alergias, método para su obtención y empleo en el tratamiento de las mismas |
US20060110435A1 (en) * | 2002-05-08 | 2006-05-25 | Lastre Gonzalez Miriam De San | Allergy vaccine composition, production method thereof and use of same in allergy treatment |
WO2004047805A1 (es) | 2002-11-27 | 2004-06-10 | Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. | Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios. |
EP1716866A1 (en) | 2003-12-30 | 2006-11-02 | Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros | Proteoliposomes and derivatives thereof as cytotoxic response-inducing adjuvants and resulting formulations |
ES2301418A1 (es) * | 2003-12-30 | 2008-06-16 | Instituto Finlay. Centro De Investigacion-Producci | Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotoxica y las formulaciones resultantes. |
Non-Patent Citations (24)
Title |
---|
BARTLETT, J BIOL CHEM, vol. 234, 1959, pages 466 |
BRANDTZAEG P ET AL., IMMUNOL TODAY, vol. 20, 1999, pages 141 - 151 |
BRANDTZAEG P., INT. J. MED. MICROBIOL., vol. 293, 2003, pages 3 - 15 |
BRANDTZAEG P., PABST R., TRENDS IN IMMUNOLOGY, vol. 25, no. 11, 2004, pages 570 - 577 |
DALSEG R. ET AL.: "Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice.", VACCINE., vol. 17, 1999, pages 2336 - 2345, XP004168964 * |
EISENBARTH SC ET AL., NATURE, vol. 453, 2008, pages 1122 - 1126 |
FLUMIST, BELSHE RB, MENDELMAN PM, TREANOR J, KING J, GRUBER WC, PIEDRA P ET AL., NEJM, vol. 338, 1998, pages 11405 - 12 |
GIANNASCA P. J. ET AL., INFECTION AND IMMUNITY, vol. 67, no. 2, 1999, pages 527 - 538 |
GONZÁLEZ E. ET AL.: "Mucosal and systemic immune response against Neisseria meningitidis B induced by single time vaccination strategy.", VACCIMONITOR., vol. 18, no. 2, May 2009 (2009-05-01), XP008149172 * |
PASHINE A, VALIANTI NM, NAT MED, vol. 11, 2005, pages 63 - 68 |
PEREZ ET AL., SCAND J IMMUNOLOGY, vol. 66, 2007, pages 271 - 77 |
PEREZ O ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 82, 2004, pages 603 - 610 |
PEREZ O ET AL., INFECT IMMUN., vol. 69, no. 7, 2001, pages 4502 - 4508 |
PEREZ O ET AL., SCAND J IMMUNOLOGY, vol. 66, 2007, pages 271 - 77 |
PEREZ O. ET AL., PHARMACOLOGYONLINE, vol. 3, 2006, pages 762 - 64 |
PEREZ O. ET AL.: "New vaccines require potent adjuvants like AFPLl and AFCol.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY., vol. 66, 2007, pages 271 - 277, XP008149175 * |
PÉREZ O. ET AL.: "Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern.", IMMUNOLOGY AND CELL BIOLOGY., vol. 82, 2004, pages 603 - 610, XP008108782 * |
PETERSON, ANALYT. BIOCHEM., vol. 83, 1977, pages 346 |
RANASINGHE CH. ET AL., VACCINE, vol. 24, 2006, pages 5881 - 5895 |
RODRIGUEZ T ET AL., VACCINE, vol. 26, 2005, pages 1312 - 21 |
See also references of EP2359850A4 |
SINGH M, 0 'HAGAN DT, PHARM. RES, vol. 19, no. 6, 2002, pages 715 - 728 |
SINGH M, O'HAGAN DT, PHARM. RES, vol. 19, no. 6, 2002, pages 715 - 728 |
VOGEL FR, DEV. BIOL. STAND., vol. 92, 1998, pages 241 - 248 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200345825A1 (en) * | 2017-12-26 | 2020-11-05 | Universidad De Chile | Formulation of fish vaccine based on lipidic nanovesicles, in particular, a proteoliposome or cochleate, with activity against the salmonid rickettsial syndrome (srs) |
Also Published As
Publication number | Publication date |
---|---|
CA2744048A1 (en) | 2010-05-27 |
EP2359850A4 (en) | 2014-05-14 |
CN102497879A (zh) | 2012-06-13 |
EP2359850A1 (en) | 2011-08-24 |
US20110256214A1 (en) | 2011-10-20 |
AU2009317725A1 (en) | 2010-05-27 |
CU20080215A7 (es) | 2012-06-21 |
BRPI0921578A2 (pt) | 2019-09-24 |
ZA201103645B (en) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2369550T3 (es) | Formulación de adyuvante para administración en mucosas. | |
TWI421091B (zh) | 包含以聚肌苷酸-聚胞苷酸為主之佐劑的黏膜免疫物質 | |
US20070166800A1 (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
ES2893584T3 (es) | Adyuvante para vacunas, vacuna y procedimiento de inducción de inmunidad | |
WO2010057447A1 (es) | Vacunas unitemporales | |
WO2013138334A1 (en) | Adjuvant and vaccine compositions | |
JP2018135388A (ja) | シュードモナス抗原および抗原の組み合わせ | |
Wilson et al. | A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection | |
ES2346441T3 (es) | Composiciones y procedimientos para activar una inmunidad innata y alergica. | |
Alfandari et al. | Transforming parasites into their own foes: parasitic extracellular vesicles as a vaccine platform | |
RU2736642C2 (ru) | Липосомальные адъювантные композиции | |
KR101599281B1 (ko) | 폐렴연쇄상구균 유래 막소포체를 포함하는 폐렴연쇄상구균 백신 조성물 | |
Reginald et al. | Current practices and future trends in cockroach allergen immunotherapy | |
WO2017156378A1 (en) | Single dose non-adjuvanted cutaneous tetanus vaccine and uses thereof | |
MX2008008967A (es) | Sustancias inmunogenicas mucosales que comprenden un adyuvante a base de acido poliinosinico-acido policitidilico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980154798.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09827196 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 970/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2744048 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009317725 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009317725 Country of ref document: AU Date of ref document: 20091119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009827196 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13130146 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0921578 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110518 |